Full history for every metric is available with a Kvantra account
Cel AI PLC (CLAI.L)
Key financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -2 | |||||
| Net profit | £m | -0 | -0 | -3 | -6 | -3 | -2 |
| EPS reported | £ | -0.00 | |||||
| Operating cashflow per share | £ | -0.00 | |||||
| Capex per share | £ | 0.00 | |||||
| FCF per share | £ | -0.00 | |||||
| Free cash flow | £m | -2 | |||||
| Net debt | £m | -0 | |||||
| Book value equity | £m | 1 | |||||
| Book value per share | £ | 0.00 | |||||
| Number of shares | m | 602.25 | |||||
| DPS (TTM paid) | £ | 0.00 |
Financial summary
Financials in GBP| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 1.05 | |||||
| P/S LTM | x | 30.21 | |||||
| P/FCF LTM | x | -0.36 | |||||
| EV/EBITDA LTM | x | -0.28 | |||||
| EV/Sales LTM | x | 18.30 | |||||
| Earnings Yield LTM | % | -337.15% | |||||
| FCF Yield | % | -276.92% | |||||
| Quality | |||||||
| ROE | % | -355.15% | |||||
| ROIC | % | -359.34% | |||||
| Operating margin | % | -10305.3% | |||||
| Gross margin | % | 57.18% | |||||
| FCF/Sales | % | -8365.8% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -73.31% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | - | |||||
| Net Debt/EBITDA | x | 0.18 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -39.41% | |||||
| Net debt/Equity | x | -0.42 | |||||
| Gross debt/equity | x | 0.00 | |||||
Company overview
Operating with its subsidiaries, Cel AI PLC produces and distributes consumer items infused with biosynthetic cannabinoids across the United Kingdom. Their product range includes cannabinoid-based solutions designed for both topical skincare and ingestible applications. These goods reach consumers through various channels: traditional retailers, direct online sales via the company's website, and other digital platforms. The organization, which began trading in 2018, was formerly named Cellular Goods PLC before officially adopting the Cel AI PLC moniker in February 2024. Its operational base is located in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cel AI PLC (CLAI.L)
Operating with its subsidiaries, Cel AI PLC produces and distributes consumer items infused with biosynthetic cannabinoids across the United Kingdom. Their product range includes cannabinoid-based solutions designed for both topical skincare and ingestible applications. These goods reach consumers through various channels: traditional retailers, direct online sales via the company's website, and other digital platforms. The organization, which began trading in 2018, was formerly named Cellular Goods PLC before officially adopting the Cel AI PLC moniker in February 2024. Its operational base is located in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free